Dong-A ST stated that its R&D expertise has been reaffirmed by the positive CHMP opinion, following the FDA approval for ...
Accord Healthcare Limited (Accord) announces that the Committee for Medicinal Products for Human Use (CHMP) of the European ...
At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...
GlobalData on MSN5d
Lilly touts Omvoh’s superiority over J&J’s Stelara in Crohn’sStelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its ...
Johnson & Johnson's immunology superstar Stelara and oncology blockbuster Darzalex have long been among the company's top ...
J&J's Q3 2024 earnings beat expectations with $22.5B in revenue, driven by strong performances from Darzalex, STELARA, and ...
On a mission to collect a key Crohn’s disease approval and build out its inflammatory bowel disease (IBD) profile, Eli Lilly ...
Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.
Before administering your dose of Stelara at home always check to make sure the medication is within its expiration date. If the expiration date has passed or the medication is cloudy, do not use it.
Pharmaceutical Technology on MSN9d
South Korean company Dong-A ST wins FDA approval for Stelara biosimilarImuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.
Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.
Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback